Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives
Pia Villa, Lars Torup(University of Messina), Marcel Leist(University of Konstanz), Anthony Cerami(Araim Pharmaceuticals (United States)), Michael Brines(Northwell Health), Pietro Ghezzi(Brighton and Sussex Medical School), Johan van Beek(Biogen (Switzerland)), Jens Gerwien(University of Messina), Anna Kirstine Larsen(University of Messina), Søren Christensen(Lundbeck (Denmark))
Cited by 153
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Clinical Relevance of Biomarkers of Oxidative Stress
|Antioxidants and Redox Signaling|2015|906